Nasal polyposis is a risk factor for nonadherence to CPAP treatment in sleep apnea: the population-based DISCOVERY study

• Published in: Journal of clinical sleep medicine Vol. 19; no. 3; pp. 573 - 579
• Main Authors: Bengtsson, Caroline, Grote, Ludger, Ljunggren, Mirjam, Ekström, Magnus, Palm, Andreas
• Format: Journal Article
• Language: English
• Published: United States American Academy of Sleep Medicine 01.03.2023
• Subjects: adherence; chronic rhinosinusitis; Clinical Medicine; Continuous Positive Airway Pressure - methods; CPAP; Female; Humans; Klinisk medicin; Lungmedicin och allergi; Male; Medical and Health Sciences; Medicin och hälsovetenskap; nasal obstruction; nasal polyposis; Neurosciences; Neurosciences & Neurology; Neurovetenskaper; Nose; Patient Compliance; population-based; positive airway pressure; Registries; Respiratory Medicine and Allergy; Risk Factors; Scientific Investigations; Sleep Apnea, Obstructive - therapy; nasal obstruction; CPAP; adherence; nasal polyposis; population-based
• ISSN: 1550-9389; 1550-9397; 1550-9397
• DOI: 10.5664/jcsm.10390

The aim was to evaluate nasal polyposis as a risk factor for nonadherence to continuous positive airway pressure (CPAP) treatment in patients with obstructive sleep apnea (OSA). This was a population-based, longitudinal analysis of patients starting CPAP treatment for OSA in the Swedish quality registry Swedevox between 2010 and 2018. Data were cross-linked with national registries. The impact of nasal polyposis on CPAP adherence was analyzed using uni- and multivariable logistic and linear regression models. Relevant confounders (age, sex, usage of nasal and oral steroids) were identified using a direct acyclic graph. Of 20,521 patients with OSA on CPAP treatment (29.5% females), 331 (1.6%) had a diagnosis of nasal polyposis at baseline. At the 1-year follow-up, nasal polyposis was associated with an increased risk of CPAP usage < 4 hours/night (unadjusted odds ratio [OR] 1.21; 95% confidence interval [CI] 0.95-1.55); adjusted OR 1.38; 95% CI 1.08-1.77). In this group, unadjusted nocturnal mean CPAP usage was 15.4 minutes (95% CI -31.62 to 0.83) shorter and was an adjusted 24.1 minutes (95% CI -40.6 to -7.7) shorter compared with patients with OSA without nasal polyposis. Nasal polyposis is associated with reduced CPAP usage per night. These results highlight the importance of diagnosing nasal polyposis in patients with OSA before the start of CPAP treatment. Treatment of the condition may improve adherence, efficacy, and patient outcomes. Bengtsson C, Grote L, Ljunggren M, Ekström M, Palm A. Nasal polyposis is a risk factor for nonadherence to CPAP treatment in sleep apnea: the population-based DISCOVERY study. . 2023;19(3):573-579.